Connect with us

Industry News

Aura Announces Closing of Non-Brokered Private Placement

Avatar

Published

on

default_cannabis_industry_cannamaps

TORONTO, Jan. 11, 2019 (GLOBE NEWSWIRE) — Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce that on January 10, 2019 (the “Closing Date”) it closed its previously announced non-brokered private placement raising gross proceeds of $1,724,099.85 (the “Offering”). The Offering was upsized from $1,500,000, as announced on January 8, 2019. The net proceeds from the Offering shall be used for general working capital and to advance the Company’s involvement in two Israeli cannabis companies, HolyCanna and CannabiSendak.
Upon closing, the Company issued 11,493,999 units of the Company (each, a “Unit” and collectively, the “Units”). Each Unit was sold at a price of $0.15 and was comprised of one common share in the capital of the Company (each a “Common Share”) and one-half of one common share purchase warrant, exercisable at $0.25 for a period of 24 months from the Closing Date.Finder’s CompensationIn connection with the Offering, the Company issued 122,160 non-transferable finders warrants (each a “Finder’s Warrant”) and paid a cash fee to finders in the amount of $18,324. Each Finder’s Warrant is exercisable at a price of $0.25 to purchase one Common Share for a period of 24 months from the Closing Date.Related Party Participation in the OfferingDaniel Cohen, Chief Executive Officer of Aura, subscribed to 400,000 Units and Howard Brass, Chief Operating Officer of Aura, subscribed to 100,000 Units  (together, the “Related Parties”). Such participation is considered to be a related party transaction within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). However, this related party transaction is exempt from minority approval, information circular and formal valuation requirements pursuant to Sections 5.5(c) and 5.7(b) of MI 61-101, since:the Offering was a distribution of securities for cash;neither the Company nor, to the knowledge of the Company after reasonable inquiry, the Related Parties, have knowledge of any material information concerning the Company or its securities that has not been generally disclosed; andneither the fair market value of the Units distributed pursuant to the Offering nor the consideration paid by the Related Parties exceeded $2,500,000.All securities issued in connection with the Offering will be subject to a hold period of four months plus one day from the Closing Date. The Offering remains subject to the approval of the Canadian Securities Exchange.About Aura Health Inc.Aura is building an international network of vertically integrated cannabis assets. The Company holds convertible debt that converts to 54% equity of HolyCanna, a cultivation and nursery license holder in Israel, and has an LOI in place to acquire the majority of CannabiSendak, the builder of a network of high-profile dispensaries in Israel. Aura also owns a 30% interest in four medical marijuana clinics in the U.S. Sun Belt, with an option to increase its interest in three of the clinics to 51%.For further information, please contact:Daniel Cohen, CEO
Aura Health Inc.
(647) 202-1824
David Posner, Chairman
Aura Health Inc.
(647) 985-6727
Caution Regarding Forward-Looking Information:THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe and to the satisfaction of the relevant regulators, completing the acquisition of the applicable real estate and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Original story can be found at: http://globenewswire.com/news-release/2019/01/11/1690440/0/en/Aura-Announces-Closing-of-Non-Brokered-Private-Placement.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Hemptown Announces Private Placement of Up to CDN$15 Million

Avatar

Published

on

default_cannabis_industry_cannamaps

VANCOUVER, British Columbia, June 19, 2019 (GLOBE NEWSWIRE) — HEMPTOWN ORGANICS CORP. (Hemptown” or the “Company“) is pleased to announce the Company has entered into an agreement with Canaccord Genuity Corp. (“Canaccord Genuity”) pursuant to which Canaccord Genuity has agreed to act as lead agent on behalf of a syndicate of investment dealers to be named (together with Canaccord Genuity, the “Agents”) in connection with a best efforts offering (the “Brokered Offering”) of units of the Company (the “Units”) at a price of CDN$2.25 per Unit, for gross proceeds of up to CDN$7,500,000.
Alongside the Brokered Offering, the Company is also undertaking a non-brokered offering (the “Non-Brokered Offering”) of up to an additional CDN$7,500,000 in Units on the same terms as the Brokered Offering.Each Unit will consist of one common share (a “Unit Share”) and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”) of the Company. Each Warrant shall be exercisable to acquire one common share of the Company (a “Warrant Share”) at an exercise price of CDN$5.00 per Warrant Share for a period of 36 months from the closing date, subject to adjustment in certain events.Commenting on the offering, John Cummings, CEO of Hemptown, stated, “Hemptown is positioned to become a vertically integrated company – from soil (over 1,500 acres of farm capacity) to oil (extraction and processing facilities) to shelf (manufacturing and distribution of branded and white-labelled products). In a burgeoning market expected to exceed $22 billion by 2020, the key to success is the ability to control the supply chain while developing superior market-ready products. This capital will position the company to do exactly that.”Hemptown is presently positioned to be one of the largest producers of CBG in North America. CBG is the precursor to the main cannabinoids (THCA, CBDA, CBCA) and is commonly known as “The Mother of All Cannabinoids.” Hemptown is growing over 500 acres focused exclusively on these rare genetics and is projecting to be a key North American supplier of CBG by the end of 2019.About Hemptown Organics Corp.Hemptown is producing some of the finest cannabinoid products in the world. Following an impressive first year yield, the Company is scaling up its operation to meet domestic and international demand. With expansion of farmland, in-house extraction/processing facilities and a branded product line, Hemptown’s vertically integrated business model is well-positioned to capitalize on a global market expected to exceed $22 billion by 2020.Disclaimer for Forward-Looking StatementsThis news release contains forward-looking statements that involve various risks and uncertainties regarding future events. Such forward-looking statements are based on current expectations of management, involve a number of risks and uncertainties, and are not guarantees of future performance of the Company. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “will”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing date of the Financing, the attributes of the securities to be offered and sold by the Company and the proposed use of the net proceeds of the Financing. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors that may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include general market conditions, significant business, competitive, political and social risks and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.This press release does not constitute an offer to sell or a solicitation of an offer to buy ‎nor shall there be any sale of any of the securities in any jurisdiction in which such ‎offer, solicitation or sale would be unlawful. The securities have not been and will not ‎be registered under the United States Securities Act of 1933, as amended (the “U.S. ‎Securities Act”), or the securities laws of any state of the United States and may not be ‎offered or sold within the United States (as defined in Regulation S under the U.S. ‎Securities Act) unless registered under the U.S. Securities Act and applicable state ‎securities laws or pursuant to an exemption from such registration requirements.Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/06/19/1871453/0/en/Hemptown-Announces-Private-Placement-of-Up-to-CDN-15-Million.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Segra Appoints Robotics and Automation Expert Dr. Edward Park to Advisory Board

Avatar

Published

on

default_cannabis_industry_cannamaps

VANCOUVER, British Columbia, June 19, 2019 (GLOBE NEWSWIRE) — Segra International Corp. (“Segra” or the “Company”) an agriculture technology company, is pleased to announce the addition of Dr. Edward J. Park to its Board of Advisors.
A Ph.D. and M.A.Sc. graduate of the University of Toronto, Dr. Park adds years of mechatronics and automation engineering experience to Segra’s Advisory Board. Segra’s forthcoming tissue culture nurseries, built for industrial-scale production of disease-free and DNA fingerprinted cannabis plantlets, will be designed with partial automation of product flow. Dr. Park is currently a renowned Professor of Mechatronic Systems Engineering at Simon Fraser University in British Columbia.“We are pleased to welcome a peer of Dr. Park’s esteem to our organization,” said Dr. Sma Zobayed, Segra’s Director of Tissue Culture. “Plant tissue culture is a precise science that employs trained technicians – those technicians, in turn, depend on sterile equipment made available through automation. Segra’s planned operations necessitate implementing the kinds of technology that Dr. Park has spent his career researching and developing.”Segra’s 4,000 sq. ft. “Phase 1” production facility in New Westminster, B.C., is anticipated to begin plant tissue culture operations under a Nursery License from Health Canada in Q3 2019. The Company’s planned “Phase 2” production facility is expected to be a 42,000 sq. ft. space designed for production capacity in excess of 30 million plantlets per year. The Company also recently announced an expansion into the U.S. hemp market, providing hemp tissue culture services out of the Company’s new laboratory facility in Portland, Oregon.About Segra InternationalSegra is an agriculture technology company offering innovative services that accelerate the advancement of the cannabis industry to better serve society. The Company’s plant tissue culture and genomics technologies, coupled with a vast business ecosystem, empower its clients to drive financial performance and mitigate risk, while exploring the next frontiers of optimized cultivation practices for the rapidly evolving medical, recreational, and hemp markets. Segra is developing industrial-scale facilities to produce disease-free, robust, and DNA fingerprinted cannabis plantlets for licensed producers globally. To support this vision, Segra has assembled a world-class team of specialists in the fields of agronomy, molecular genetics, plant tissue culture, and regulatory compliance. Segra currently has agreements with many leading global cannabis producers, including the Canadian licensed producers HEXO Corp., Agripharm Corp., and The Supreme Cannabis Company Inc.Forward-looking informationThis news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.For further information, contact:Sam WoolfInvestor Relations and Communications ManagerEmail: sam.woolf@segra-intl.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/06/19/1871426/0/en/Segra-Appoints-Robotics-and-Automation-Expert-Dr-Edward-Park-to-Advisory-Board.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

NutraNomics, Inc. (NNRX) Announces Establishment of UK and Domestic Subsidiaries for Expansion and Farming Opportunities Along with a New Huntington Beach, California Headquarters

Avatar

Published

on

default_cannabis_industry_cannamaps

Portland, OR, June 19, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraNomics, Inc. (NNRX) announces establishment of UK and Domestic Subsidiaries for expansion and farming opportunities along with a new Huntington Beach, California Headquarters.
NutraNomics is please to announce the formation of our International Division and our first farming subsidiary in the United States. NutraNomics UK LLC Limited is the newly formed, wholly owned, international presence for NNRX designed to encourage international partnerships and agricultural funding opportunities. Established in the United Kingdom, the entity will hold and transact our international opportunities by providing a more attractive home for international investment interests. We have secured significant investment opportunities that can fund large scale operations meeting specific criteria. NNRX is in the process of packaging farming opportunities to present, should we opt to exercise this source of funding. We are also reviewing and vetting several other opportunities for hemp cultivation internationally that fit the standards set by this funder.  NutraNomics UK LLC Limited will be the entity for all Caribbean, South American, African and European farming operations currently under analysis. The phased approach to our ‘Eco-Campus’ entails tranches of expansion, starting with farming and expanding to extraction and greenhouses. This will provide NNRX with the opportunity to grow into the international markets as each country defines how they will handle sale and export of biomass, fiber and extracts associated with growing hemp. “It is clear the market demand for hemp, both Medical and Industrial, will be no closer to being filled in 2019 and 2020. This shortage provides a unique opportunity for NutraNomics to respond to market demand while building out our farming and extraction,” says Jonathan Bishop, CEO of NutraNomics. “The potential legality and distribution issues that surround CBD extracts in the US, or at the very least the cloudy nature of FDA approval as compared to the international community, gives us the confidence that the diversification of our farming operations is not only right, it is necessary for the immediate and long term growth of the company.” BioMedical Holdings, LLC is the first of our farming subsidiaries and will hold our initial farming opportunities. We should be in a position to announce specifics with regards to 2019 farming by mid-July.  Our first domestic farming locations are anticipated to be primarily in the western United States. This acreage should be perfected shortly and will be announced when fully signed and funded. NutraNomics continues to be one of the few, if not the only company approaching the hemp harvest with a dual approach to profit potential. The separation of cola (flowers) from stalk and stem at harvest provides ‘chunky biomass’ for extraction with higher CBD content than if processed with the whole plant, while rendering stalk and stem for use in the industrial market, something unique to the industry thus far. Other operations have separated the stalk from the cola and provide chunky biomass for extraction, but none are further processing the stalk and stem for sale to the commodities markets that need hemp. Our Wholesale Materials Division will be managing the sale of all products created in association with hemp cultivation efforts. Expansion of our corporate footprint has begun with the establishment of new California Corporate Headquarters in Huntington Beach, CA.  Future offices are planned for Orange County, new office location in Portland, OR, and our Wholesale Materials Sales Division in Worster, MA. NutraNomics will announce our 2019 Shareholder Meeting once dates at the end of summer are identified. Safe Harbor StatementThis press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results or implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company’s control. Forward-looking statements speak only as to the date they are made and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.Jonathan Bishop  CEO  NutraNomics Inc.  www.NutraNomics.comir@nutranomics.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/06/19/1871379/0/en/NutraNomics-Inc-NNRX-Announces-Establishment-of-UK-and-Domestic-Subsidiaries-for-Expansion-and-Farming-Opportunities-Along-with-a-New-Huntington-Beach-California-Headquarters.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending